{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:47:37Z","timestamp":1790891257795,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bmc.2021.116033","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T06:33:44Z","timestamp":1611297224000},"page":"116033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-9595","authenticated-orcid":false,"given":"Kazuo","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Tatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hiratochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-3012","authenticated-orcid":false,"given":"Hidemasa","family":"Hikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Azumaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Isaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116033_b0005","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.bmc.2021.116033_b0010","unstructured":"How Does Diabetes Affect The Body? http:\/\/www.diabetes.co.uk\/how-does-diabetes-affect-the-body.html (accessed 6.December 2020)."},{"key":"10.1016\/j.bmc.2021.116033_b0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.04.061","article-title":"Current anti-diabetic agents and their molecular targets: A review","volume":"152","author":"Kerru","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2021.116033_b0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition \u2014 a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.bmc.2021.116033_b0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11892-010-0095-5","article-title":"Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors","volume":"10","author":"Patel","year":"2010","journal-title":"Curr Diab Rep"},{"issue":"12","key":"10.1016\/j.bmc.2021.116033_b0030","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.bmc.2021.116033_b0035","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2019.09.022","article-title":"Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection","volume":"74","author":"Cherney","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.bmc.2021.116033_b0040","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta\u2010analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bmc.2021.116033_b0045","doi-asserted-by":"crossref","first-page":"112523","DOI":"10.1016\/j.ejmech.2020.112523","article-title":"An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent","volume":"204","author":"Bhattacharya","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"15","key":"10.1016\/j.bmc.2021.116033_b0050","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1080\/14656566.2020.1793961","article-title":"An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes","volume":"21","author":"Chatzopoulos","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.bmc.2021.116033_b0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.bmc.2021.116033_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/DMSO.S22503","article-title":"Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus","volume":"5","author":"Whaley","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.bmc.2021.116033_b0065","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"6316","key":"10.1016\/j.bmc.2021.116033_b0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/350354a0","article-title":"Glucose\/galactose malabsorption caused by a defect in the Na+\/glucose cotransporter","volume":"350","author":"Turk","year":"1991","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.bmc.2021.116033_b0075","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1021\/jm990175n","article-title":"Na +-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4\u2018-Dehydroxyphlorizin Derivatives Substituted on the B Ring","volume":"42","author":"Tsujihara","year":"1999","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bmc.2021.116033_b0080","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1016\/j.bmc.2012.09.037","article-title":"Structure\u2013activity relationship studies of 4-benzyl-1H-pyrazol-3-yl \u03b2-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia","volume":"20","author":"Fushimi","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116033_b0085","unstructured":"The crystal structures of 8b has been deposited at the Cambridge Crystallographic Data Centre and the CCDC deposition number are 2034277."},{"key":"10.1016\/j.bmc.2021.116033_b0090","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1248\/cpb.c15-00982","article-title":"O-Glycosylation of 4-(substituted benzyl)-1,2-dihydro-3H-pyrazol-3-one derivatives with 2,3,4,6-tetra-O-acyl-\u03b1-d-glucopyranosyl bromide via N1-acetylation of the pyrazole ring","volume":"64","author":"Kobayashi","year":"2016","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"10.1016\/j.bmc.2021.116033_b0095","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1021\/jm960444z","article-title":"New potent antihyperglycemic agents in db\/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl)pyrazoles and -pyrazolones","volume":"39","author":"Kees","year":"1996","journal-title":"J Med Chem."},{"issue":"14","key":"10.1016\/j.bmc.2021.116033_b0100","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/S0960-894X(03)00466-9","article-title":"Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors","volume":"13","author":"Ohsumi","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2021.116033_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj0570001","article-title":"The influence of structure on the hydrolysis of substituted phenyl \u03b2-d-glucosides by emulsin","volume":"57","author":"Nath","year":"1954","journal-title":"Biochem J."},{"issue":"1","key":"10.1016\/j.bmc.2021.116033_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07700-1","article-title":"Inhibitor binding mode and allosteric regulation of Na+-glucose symporters","volume":"9","author":"Bisignano","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bmc.2021.116033_b0115","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1021\/jm9905460","article-title":"Probing the Conformation of the Sugar Transport Inhibitor Phlorizin by 2D-NMR, Molecular Dynamics Studies, and Pharmacophore Analysis","volume":"43","author":"Wielert-Badt","year":"2000","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bmc.2021.116033_h0120","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1016\/j.bmcl.2005.08.067","article-title":"Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1","volume":"15","author":"Zhang","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2021.116033_h0125","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bmcl.2005.12.006","article-title":"Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2","volume":"16","author":"Zhang","year":"2006","journal-title":"Bioorg Med Chem Lett."},{"key":"10.1016\/j.bmc.2021.116033_b0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1248\/cpb.46.22","article-title":"Na+-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4'-dehydroxyphlorizin derivatives","volume":"46","author":"Hongu","year":"1998","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"10.1016\/j.bmc.2021.116033_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111773","article-title":"Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review","volume":"184","author":"Haider","year":"2019","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmc.2021.116033_b0135","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ejmech.2017.10.049","article-title":"Optimization of pharmacokinetic properties by modification of a carbazole-based cannabinoid receptor subtype 2 (CB2) ligand","volume":"143","author":"Heimann","year":"2018","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmc.2021.116033_b0140","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.2147\/DDDT.S221093","article-title":"Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy","volume":"14","author":"Mohan","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2021.116033_h0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2011.01462.x","article-title":"Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients","volume":"14","author":"Dobbins","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.bmc.2021.116033_h0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2050-6511-14-25","article-title":"Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus","volume":"14","author":"Hussey","year":"2013","journal-title":"BMC Pharmacol Toxicol."},{"key":"10.1016\/j.bmc.2021.116033_h0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.12391","article-title":"Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes","volume":"17","author":"Sykes","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.bmc.2021.116033_h0165","first-page":"587","article-title":"Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind","volume":"80","author":"Dharmalingam","year":"2020","journal-title":"Active-Controlled Trial. Drugs."},{"key":"10.1016\/j.bmc.2021.116033_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","article-title":"Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence","volume":"13","author":"Bonora","year":"2020","journal-title":"Diabetes Metab Syndr Obes."},{"key":"10.1016\/j.bmc.2021.116033_b0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jceh.2015.02.005","article-title":"Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice","volume":"5","author":"Nakano","year":"2015","journal-title":"J Clin Exp Hepatol."},{"key":"10.1016\/j.bmc.2021.116033_b0160","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1021\/jo971176v","article-title":"NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities","volume":"62","author":"Gottlieb","year":"1997","journal-title":"J Org Chem."},{"key":"10.1016\/j.bmc.2021.116033_b0165","series-title":"Spectrometric Identification of Organic Compounds","author":"RobertSilverstein","year":"2005"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:13:00Z","timestamp":1760836380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":37,"alternative-id":["S0968089621000419"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116033","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116033"}}